Pharmaceutical News

RSS

OSU unveils new online course for pharmacists

Oregon State University (OSU) has unveiled an online course for pharmacists, designed to improve their management and human resource abilities while providing a valuable continuing education opportunity.

16 Jun 2012

Patients with NK/T-cell lymphomas might benefit from treatment with JAK inhibitors

A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

16 Jun 2012

New approach to drug design may yield more effective and less toxic cancer medicines

A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco (UCSF) and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.

16 Jun 2012

Nouveau Life explores line of specialty supplements for seniors

Nouveau Life Pharmaceuticals, Inc., a provider of quality all-natural dietary supplements, announced today that the Company is exploring a line of specialty supplements for seniors.

15 Jun 2012

Take home MMT may reduce hospital admissions

A recent study conducted by researchers at Boston Medical Center (BMC) shows that patients receiving "take home" methadone maintenance treatment (MMT) were less likely to be admitted to the hospital as compared to those not receiving take home doses.

15 Jun 2012

Drug safety warnings by FDA do not always lead to targeted changes

Drug safety warnings issued by the U.S. Food and Drug Administration (FDA) don't always lead to targeted changes in the way medications are prescribed and used, reports a study in the June issue of Medical Care.

15 Jun 2012

Osiris receives consent from NZ to market Prochymal for GvHD

Osiris Therapeutics, Inc., announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

15 Jun 2012

Impel NeuroPharma announces important POD technology milestones

Impel NeuroPharma, a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier (BBB) using direct nose-to-brain delivery, today announced a set of important milestones in its drive to commercialize its POD technology.

15 Jun 2012

Digoxin can protect against high blood pressure and heart failure

An ancient heart drug that's inspired the work of herbalists and poets for centuries may treat a condition that plagues millions of overstressed and overweight Americans today.

15 Jun 2012

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures, LLC today announced the formation of Global Blood Therapeutics, Inc. and its $40.7 million Series A financing of the company.

15 Jun 2012

FDA approves GSK’s MenHibrix to treat meningococcal and Hib diseases

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved the vaccine MenHibrix [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine].

15 Jun 2012

FDA approves Menhibrix for vaccination against meningococcal and Hib diseases

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b.

15 Jun 2012

IBMT linked with positive structural changes in brain connectivity

A Texas Tech University scientist studying the Chinese mindfulness meditation known as integrative body-mind training (IBMT) said he and other researchers have confirmed and expanded on changes in structural efficiency of white matter in the brain that can be related to positive behavioral changes in subjects practicing the technique for a month and a minimum of 11 hours total.

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Study shows how cisplatin prevents clumping of hSOD1 linked to ALS

A long-used anti-cancer drug could be a starting point to develop new treatments for the incurable nerve disease known as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), scientists are reporting.

14 Jun 2012

Brazilian researchers say schistosomiasis vaccine could be available in 3 years

"Brazilian researchers say they have successfully tested a vaccine against schistosomiasis, a disease caused by parasitic worms that afflicts more than 200 million people worldwide," Agence France-Presse reports.

14 Jun 2012

Innovimmune receives $600,000 NIH grant to develop MIF inhibitors for RA

Specialty drug discovery company, Innovimmune Biotherapeutics, Inc. has been awarded a $600,000 Advanced Technology Small Business Innovation Research Grant from the National Institutes of Health (NIH).

14 Jun 2012

New analogues effective in inhibiting NOS activity in Parkinson models

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

14 Jun 2012

EvaluatePharma releases World Preview 2018 report

EvaluatePharma, the premier provider of pharmaceutical and biotech analysis including consensus forecasts, today released its World Preview 2018 report, providing an in-depth look at how the patent cliff will reshape the drug industry over the next six years — with valuable insight into which companies and products will come out as winners.

14 Jun 2012

Interactive website improves parental compliance with asthma controller medication use

Asthma is the most common chronic illness in adolescents and children, affecting an estimated seven million children up to the age of 17 in the United States. The burden of asthma on children is substantial: kids with asthma have a three-fold greater risk of school absence than children without asthma, and asthma is the third leading cause of hospitalization among children under the age of 15.

14 Jun 2012